Glenmark Pharmaceuticals Ltd

The launch follows the European Commission's marketing authorisation granted to Cassiopea S.p.A., a subsidiary of Cosmo N.V., in October 2025 for use in adults and adolescents aged 12 to under 18 years, with adolescent use limited to facial application. Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the product is being introduced through a strategic partner. The company is also advancing additional launches through strategic partnerships across other European markets. The product is approved in the European Union for the treatment of acne vulgaris in both adults and adolescents. It has been developed by Cassiopea, which holds the rights across Europe and works with regional partners for commercialisation. Acne vulgaris is one of the most common dermatological conditions globally, with more than 95% of males and 85% of females experiencing it during adolescence. Around 50% of individuals continue to experience acne into adulthood. The condition can have significant physical and psychological effects, particularly among adolescents and young adults. Winlevi is the first topical acne therapy in over 40 years with a first-in-class mechanism of action. Its active ingredient, clascoterone, is a topical androgen receptor inhibitor that works locally in the sebaceous glands to reduce sebum production and inflammation without systemic anti-androgen effects, supporting safe use in both males and females. The availability of the therapy provides an additional treatment option for healthcare professionals and patients across Europe. The launch marks an important milestone in Glenmark's dermatology growth strategy and reflects its continued focus on expanding access to differentiated therapies across global markets. It also strengthens the company's ability to execute multi-market launches in Europe through a combination of direct presence and strategic partnerships. Giovanni Di Napoli, Chief Executive Officer of Cosmo, commented, 'The European launch of Winlevi' represents an important milestone for Cosmo and reflects the strength of our collaboration with Glenmark. This achievement supports our strategy of expanding the global reach of our innovative dermatology portfolio through trusted partnerships and disciplined execution. We are pleased to see Winlevi' becoming available to patients across Europe and look forward to continuing to build on the momentum of our long-term partnership with Glenmark.' Jiri Havranek, Group Vice President & Business Head ' Europe, Glenmark Pharmaceuticals, commented, 'This launch is an important step in strengthening Glenmark's dermatology portfolio and advancing our branded business in the region. As Glenmark's first NCE launch in Europe, it reflects our focus on bringing differentiated treatment options to patients through disciplined execution, strong market access alignment and meaningful partnerships. We remain committed to expanding access to therapies that address unmet needs and support better outcomes for patients.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. The counter rose 0.39% to Rs 2,152.50 on the BSE. Powered by Capital Market - Live

 Glenmark Specialty S.A (GSSA), a wholly-owned subsidiary of Glenmark Pharmaceuticals, today announced the launch of Winlevi' (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to 18 years (with usage in adolescents limited to facial application) by the European Commission to Cassiopea S.p.A., a subsidiary of Cosmo N.V. (SIX: COPN) (Cosmo) in October 2025. Glenmark has initiated direct launches in several European markets, including the Nordics, Central and Eastern Europe, and Spain. In Portugal, the Company has launched the product through a strategic partner. Glenmark is also advancing additional launches through strategic partnerships across other European markets. The product is authorized in the European Union for the treatment of acne vulgaris in adults and adolescents. The product has been developed by Cassiopea, which holds rights across Europe and collaborates with regional partners for commercialization.

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat Injection, 200 mg/20 mL (10 mg/mL), of UCB Inc. According to IQVIA sales data for the 12-month period ended April 2026, the Vimpat Injection market recorded annual sales of approximately $15.2 million in the United States. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, 'The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.' Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The company reported a 6,381.9% zoom in consolidated net profit to Rs 301.41 crore on a 16.8% increase in revenue from operations to Rs 3,760.28 crore in Q4 FY26 over Q4 FY25. Shares of Glenmark Pharmaceuticals rose 0.18% to Rs 2185.30 on the BSE.Powered by Capital Market - Live

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Lacosamide Injection USP, 200 mg/20 mL (10 mg/mL), Single-Dose Vials. Glenmark's Lacosamide Injection USP is bioequivalent and therapeutically equivalent to the reference listed drug, Vimpat'2 Injection, 200 mg/20 mL (10 mg/mL), of UCB, Inc. [NDA 022254]. According to IQVIA' sales data for the 12-month period ending April 2026, the Vimpat' Injection market3 achieved annual sales of approximately $15.2 million. Commenting on the launch, Marc Kikuchi, President & Business Head, North America said, 'The launch of Lacosamide Injection USP reflects the disciplined execution of our strategy to build a broader, differentiated product portfolio in the United States. By expanding our injectable product portfolio, we are enhancing our ability to meet the evolving needs of healthcare providers while advancing our commitment to improving patient access to quality, affordable treatment options.'

Glenmark Pharmaceuticals announced that the Board of Directors of the Company at its meeting held on 29 May 2026, inter alia, have recommended the final dividend of Rs 2.5 per equity Share (i.e. 250%) , subject to the approval of the shareholders.

Revenue from operations jumped 16.8% YoY to Rs 3,760.28 crore in Q4 FY26. Profit before tax (PBT) soared to Rs 387.77 crore in Q4 FY26 from Rs 7.97 crore in Q4 FY25. EBITDA was Rs 762.6 crore in the quarter ended March 31, 2026, with EBITDA margin for the quarter at 20.2 %. Revenue from India business increased 8.2% to Rs 1,020 crore in Q4 FY26, compared with Rs 943 crore in Q4 FY25. Revenue from North America jumped 29.4% YoY to Rs 924.8 crore Revenue from Europe climbed 21.4% to Rs 890.7 crore. Revenue from emerging markets increased 13.7% to Rs 897.9 crore. For the year ended March 31, 2026, the company's consolidated net profit jumped 30.06% to Rs 1,361.85 crore in FY26 compared with Rs 1,047.09 crore in FY25. Revenue from operations jumped 27.12% YoY to Rs 16,711.40 crore in FY26. Glenn Saldanha, chairman and managing director, Glenmark Pharmaceuticals, said, 'FY26 has been a defining year in Glenmark's evolution. We delivered strong business performance while making meaningful progress against the strategic priorities that will shape our future. The landmark AbbVie partnership validated the strength of our innovation capabilities and the global relevance of our science. During the year, we expanded our portfolio of differentiated products including the successful launches of key generic respiratory products in the US which demonstrates continued expertise in our core therapeutic areas. We also accelerated the global momentum of RYALTRIS and our collaborations during FY26 reinforced our position as the partner of choice for innovative molecule launches across markets.' Separately, the board approved the transfer of the nebulizer brands and associated intellectual property assets to Glenmark Healthcare for Rs 223 crore. The transfer is expected to be completed on or before 30 June 2026. Glenmark Pharmaceuticals is engaged in the business of development, manufacturing, and marketing of pharmaceutical products, both formulations and active pharmaceutical ingredients, to regulated and semi-regulated markets. The counter dropped 4.55% to settle at Rs 2,274.25 on the BSE.Powered by Capital Market - Live

Net profit of Glenmark Pharmaceuticals rose 6381.94% to Rs 301.41 crore in the quarter ended March 2026 as against Rs 4.65 crore during the previous quarter ended March 2025. Sales rose 16.77% to Rs 3760.28 crore in the quarter ended March 2026 as against Rs 3220.13 crore during the previous quarter ended March 2025. For the full year,net profit rose 30.06% to Rs 1361.85 crore in the year ended March 2026 as against Rs 1047.10 crore during the previous year ended March 2025. Sales rose 27.12% to Rs 16711.40 crore in the year ended March 2026 as against Rs 13145.84 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3760.283220.13 17 16711.4013145.84 27 OPM %20.2817.42 -27.3617.89 - PBDT909.08506.00 80 4824.312258.04 114 PBT761.17380.79 100 4250.831772.03 140 NP301.414.65 6382 1361.851047.10 30 Powered by Capital Market - Live

Glenmark Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 29 May 2026.

Glenmark Pharmaceuticals Inc., USA (Glenmark) announced the launch of Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial. Glenmark's Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial is bioequivalent and therapeutically equivalent to the reference listed drug, Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial of Fresenius Kabi USA, LLC. According to IQVIA' sales data for the 12-month period ending March 2026, the Vancomycin Hydrochloride for Injection USP, 500 mg/vial and 1 g/vial market2 achieved annual sales of approximately $37.9 million.

Glenmark Pharmaceuticals Ltd dropped for a fifth straight session today. The stock is quoting at Rs 2289.1, down 2.48% on the day as on 13:19 IST on the NSE. The benchmark NIFTY is down around 1.15% on the day, quoting at 23542.8. The Sensex is at 75030.71, down 1.3%.Glenmark Pharmaceuticals Ltd has added around 4.38% in last one month.Meanwhile, Nifty Pharma index of which Glenmark Pharmaceuticals Ltd is a constituent, has increased around 8.83% in last one month and is currently quoting at 24170.45, down 0.5% on the day. The volume in the stock stood at 4.37 lakh shares today, compared to the daily average of 7.11 lakh shares in last one month. The benchmark May futures contract for the stock is quoting at Rs 2291.4, down 2.78% on the day. Glenmark Pharmaceuticals Ltd jumped 61.5% in last one year as compared to a 4.21% slide in NIFTY and a 12.6% spurt in the Nifty Pharma index.The PE of the stock is 44.71 based on TTM earnings ending December 25.Powered by Capital Market - Live